A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours

1. Kaufmann, S.H.E. Immunity to intracellular bacteria. Annu. Rev. Immun. 11, 129−163 (1993). | Article | PubMed  | ISI | ChemPort |
2. Cossart, P. et al. Listeriolysin O is essential for virulence of Listeria monocytogenes: Direct evidence obtained by gene complementation. Infect. Immun. 57, 3269−3636 (1989).
3. Tilney, L.G. & Portnoy, D.A. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J. Cell Biol. 109, 1597−1608 (1989). | Article | PubMed  | ISI | ChemPort |
4. Berche, P., Gaillard, J. & Sansonetti, P.J. Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell mediated immunity. J. Immun. 138, 2266−2271 (1987). | PubMed  | ISI | ChemPort |
5. Hahn, H. & Kaufmann, S.H.E. The role of cell mediated immunity to bacterial infections. Rev. infect. Dis. 3, 1221−1250 (1991).
6. Kaufmann, S.H.E., Hug, E., Vath, U. & Muller, I. Effective protection against Listeria monocytogenes and delayed type hypersensitivity to Listeria antigens depend on cooperation between specific L3T4⁺ and Lyt2⁺ T Cells. Infect. Immun. 48, 263−266 (1985). | PubMed  | ISI | ChemPort |
7. Schafer, R., Portnoy, D.A., Brassell, S.A. & Paterson, Y. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. Immun. 149, 53−59 (1992). | PubMed  | ISI | ChemPort |
8. Ikonomidis, G., Paterson, Y., Kos, F.J. & Portnoy, D.A. Delivery of a viral antigen to the class I processing and presentation pathway of Listeria monocytogenes. J. exp. Med. 180, 2209−2218 (1994). | Article | PubMed  | ISI | ChemPort |
9. Ikonomidis, G., Frankel, F.R., Portnoy, D.A. & Paterson, Y. Listeria monocytogenes: A novel live vaccine vector. in Vaccines 95, (ed. Brown, F., Charnock, R., Ginsberg, H. & Norrby, E.) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York) (in the press).
10. Boon, T., Cerottini, J.-C., Van den Eynde, B. & van der Bruggen, P. Tumour antigens recognized by T lymphocytes. Annu. Rev. Immun. 12, 337−365 (1994). | Article | PubMed  | ISI | ChemPort |
11. Coulie, P. et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. exp. Med. 180, 35−42 (1994). | Article | PubMed  | ISI | ChemPort |
12. Cox, A.L. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716−719 (1994). | PubMed  | ISI | ChemPort |
13. Gaugler, B. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. exp. Med. 179, 921−930 (1994). | Article | PubMed  | ISI | ChemPort |
14. Topalian, S.L. et al. Human CD4⁺ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. natn. Acad. Sci. U.S.A. 91, 9461−9465 (1994). | ChemPort |
15. Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into the tumor. Proc. natn. Acad. Sci. U.S.A. 91, 3515−3519 (1994). | ChemPort |
16. Fearon, E.R., Itaya, T., Hunt, B., Vogelstein, B. & Frost, P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 38, 2975−2980 (1988).
17. Murphy, G.P. & Hushresky, W.J.J. A murine renal cell carcinoma. J. natn. Cancer Inst. 50, 1013−1025 (1973). | ChemPort |
18. Schreiber, H. Tumor immunology. in Fundamental Immunology (ed. Paul, W.E.) chapt. 32 (Raven, New York, 1993).
19. Campbell, M.J., Esserman, L. & Levy, R. Immunotherapy of established murine B cell lymphoma: Combination of idiotype immunization and cyclophosphamide. J. Immun. 141, 3227−3233 (1988). | PubMed  | ISI | ChemPort |
20. Pardoll, D.M. Cancer vaccines. Trends pharmacol. Sci. 14, 202−208 (1993). | Article | PubMed  | ISI | ChemPort |
21. Asher, A. et al. Murine tumor cells transduced with the gene for tumor necrosis factor-. J. Immun. 146, 3227−3234 (1991). | PubMed  | ISI | ChemPort |
22. Blankenstein, T. et al. Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J. exp. Med. 173, 1047−1052 (1991). | Article | PubMed  | ISI | ChemPort |
23. Porgador, A. et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679−3686 (1992). | PubMed  | ISI | ChemPort |
24. Baskar, S. et al. Constitutive expression of B7 restores the immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc. natn. Acad. Sci. U.S.A. 90, 5687−5690 (1993). | ChemPort |
25. Guo, Y. et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263, 518−520 (1994). | PubMed  | ISI | ChemPort |
26. Hsieh, C.-S. et al. Development of T_H1 CD4⁺ T cells through IL-12 produced by Listeria-induced macrophages. Science 260, 547−549 (1993). | PubMed  | ISI | ChemPort |
27. Restifo, N.P. Identification of human cancers deficient in antigen processing. J. exp. Med. 177, 265−272 (1993). | Article | PubMed  | ISI | ChemPort |
28. Hui, K., Grosveld, F. & Festenstein, H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311, 750−752 (1984). | PubMed  | ISI | ChemPort |
29. Wallich, R. et al. Abrogation of metastatic properties of tumour cells by de novo expression of H-2^k antigens following H-2 gene transfection. Nature 315, 301−305 (1985). | PubMed  | ISI | ChemPort |
30. Doyle, A. et al. Markedly decreased expression of class I histocompatibility antigens, protein and mRNA on human small-cell lung cancer. J. exp. Med. 161, 1135−1151 (1985). | Article | PubMed  | ISI | ChemPort |
31. Lassam, N. & Jay, G. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J. Immun. 143, 3792−3797 (1989). | PubMed  | ISI | ChemPort |
32. Slingluff, C.L., Hunt, D.F. & Engelhard, V.H. Direct analysis of tumour-associated peptide antigens. Curr. Opin. Immun. 6, 733−740 (1994). | Article | ISI | ChemPort |
33. van der Bruggen, P.C. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643−1650 (1991). | PubMed  | ChemPort |
34. Cason, J., Khan, S.A. & Best, J.M. Towards vaccines against human papillomavirus type-16 genital infections. Vaccine 11, 603−611 (1993). | Article | PubMed  | ISI | ChemPort |
35. Wu, T.-C. Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immun. 6, 746−754 (1994). | Article | ISI | ChemPort |
36. Fetten, J.H., Roy, N. & Gilboa, E. A frameshift mutation at the NH2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. J. Immun. 147, 2697−2705 (1991). | PubMed  | ISI | ChemPort |
37. Huang, A.T.C. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961−965 (1994). | PubMed  | ISI | ChemPort |
38. Geoffroy, C. et al. Purification and characterization of an extracellular 29-kilodalton phospholipase C from Listeria monocytogenes. Infect. Immun. 59, 2382−2388 (1991). | PubMed  | ISI | ChemPort |
39. Kruisbeek, A. In vivo depletion of CD4 and CD8 specific T cells. in Current Protocols in Immunology (eds Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W.) V. 1, 4.1.1−4.1.2 (Wiley, New York, 1994).

	Top

	Top